Dedicated to improving the health and well-being of people around the world.

Sumitomo Pharma America (SMPA) drives innovative treatments, science, and technology to address patient needs in the critical areas of oncology, women's health, urology, rare disease, CNS, and cell & gene therapies.

Our Core Values

Patient First

One Diverse Team

Always with Integrity

Discover SMPA

What drives our work every single day

We build on decades of scientific rigor and an unwavering focus on what patients need.

Driven by the pursuit of innovation

Driven by the pursuit of innovation

Drug discovery, development, and commercialization must become faster and more efficient to address humanity’s pressing health needs. From advancing novel science to delivering differentiated medicines, SMPA’s commitment to meaningful innovation accelerates and guides us in our singular mission: to help patients overcome their health challenges.

Learn More
Diverse pipeline

Diverse pipeline

Our preclinical and clinical programs accelerate drug development in key areas of unique and unmet medical need across multiple therapeutic areas. We are determined to deliver better experiences for patients and caregivers on the things that matter most to them, and by doing so, we make the world a better place.

Learn More

Expertise

Where science meets care

Treatments across multiple therapeutic areas

Newsroom

The latest from SMPA

07/30/2026

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia

Read More

08/06/2026

Sumitomo Pharma America Earns 2026-2027 Great Place to Work Certification™

Read More

08/12/2026

Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa

Read More

CEO Insights

Tsutomu Nakagawa

Message from Tsutomu Nakagawa

Read

SMPA Is a Certified Great Place to Work®

We are proud to be certified as a Great Place to Work for July 2026-2027.

Great Place to Work Certified, July 2026 to July 2027, USA